

**The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS.**

**Appendix 1.** Preoperative patient characteristics and intraoperative variables for 1,583 primary total joint arthroplasty cases from 2017–2018, by development of postoperative anemia with hemoglobin < 8 g/dL\*

Variable	N (%)			P-value
	All Cases (n = 1583)	Cases with Postoperative Hemoglobin < 8 g/dL (n = 98)	Cases with Postoperative Hemoglobin ≥ 8 g/dL (n = 1485)	
Preoperative Characteristics				
Age (years)	63 ± 10 <sup>†</sup>	67 ± 13 <sup>†</sup>	63 ± 10 <sup>†</sup>	0.007
Female sex	916 (58)	74 (75.5)	842 (56.7)	<0.001
Race/ethnicity				0.008
White	1111 (70)	56 (57.1)	1055 (71.0)	
Black	340 (21)	35 (35.7)	305 (20.5)	
Asian	34 (2)	3 (3.1)	31 (2.1)	
Hispanic	30 (2)	2 (2.0)	28 (1.9)	
Other/unknown	68 (4)	2 (2.0)	66 (4.4)	
BMI value (kg/m <sup>2</sup> )	32 ± 5.3 <sup>†</sup>	29 ± 5.9 <sup>†</sup>	32 ± 5.2 <sup>†</sup>	<0.001
CCI value	3.0 ± 1.9 <sup>†</sup>	4.1 ± 2.5 <sup>†</sup>	2.9 ± 1.9 <sup>†</sup>	<0.001
Diabetes				0.001
None	1370 (87)	78 (79.6)	1292 (87.0)	
Uncomplicated	166 (10)	11 (11.2)	155 (10.4)	
End-organ damage	47 (3)	9 (9.2)	38 (2.6)	
Chronic kidney disease	109 (7)	14 (14.3)	95 (6.4)	0.003
Congestive heart failure	74 (5)	9 (9.2)	65 (4.4)	0.029
Coronary artery disease	156 (10)	15 (15.3)	141 (9.5)	0.062
Hemoglobin level (g/dL)	13 ± 1.4 <sup>†</sup>	12 ± 1.3 <sup>†</sup>	14 ± 1.4 <sup>†</sup>	<0.001
Intraoperative Variables				
Procedure type				0.037
Hip	696 (44)	53 (54.1)	643 (43.3)	
Knee	887 (56)	45 (45.9)	842 (56.7)	
General anesthesia <sup>‡</sup>	142 (9)	12 (12.2)	130 (26.8)	0.241
Tranexamic acid use	1454 (92)	80 (81.6)	1374 (92.5)	<0.001
Surgical duration (min)	110 ± 24 <sup>†</sup>	123 ± 48 <sup>†</sup>	109 ± 21 <sup>†</sup>	0.004

BMI, body mass index; CCI, Charlson Comorbidity Index.

\*Defined as a hemoglobin level < 8 g/dL.

<sup>†</sup>Expressed as mean ± standard deviation.

<sup>‡</sup>Referent is neuraxial anesthesia.

**Appendix 2:** Postoperative outcomes of 1,583 primary total joint arthroplasty cases from 2017–2018, by postoperative anticoagulation regimen.

Outcome	Postoperative Anticoagulant Regimen, N (%)					<i>P</i> -value
	All Cases (n = 1,583)	Aspirin (n = 1,337)	Coumadin (n = 59)	Enoxaparin (n = 13)	NOACs (n = 174)	
Postoperative hemoglobin <8 g/dL	98 (6.2)	77 (5.8)	4 (6.8)	3 (23)	14 (8.0)	0.062
Acute kidney injury	33 (2.1)	27 (2.0)	3 (5.1)	0 (0.0)	3 (1.7)	0.403
Length of hospital stay (h)	41 ± 27 <sup>†</sup>	40 ± 26 <sup>†</sup>	44 ± 21 <sup>†</sup>	43 ± 21 <sup>†</sup>	47 ± 31 <sup>†</sup>	0.028
ED visit/readmission within 90 d	79 (5.0)	64 (4.8)	0 (0.0)	1 (7.7)	14 (8.0)	0.048

NOAC, novel oral anticoagulant

<sup>†</sup>Expressed as mean ± standard deviation.